Market cap
$12,043 Mln
Market cap
$12,043 Mln
Revenue (TTM)
$958 Mln
P/E Ratio
--
P/B Ratio
20
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-8.3
Debt to Equity
0.6
Book Value
$26.9
EPS
$-12.9
Face value
--
Shares outstanding
22,939,969
CFO
$-1,147.99 Mln
EBITDA
$-1,462.51 Mln
Net Profit
$-1,429.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
| -8.9 | 20.3 | 5.7 | 72.3 | 30.3 | 33.6 | 44.5 |
|
BSE Sensex
| -7.3 | 4.0 | -6.1 | 1.9 | 9.1 | 10.0 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
| 88.7 | 33.0 | -20.3 | 242.5 | -23.8 | 22.0 | -19.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
|
530.2 | 12,043.3 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.0 |
| 69.5 | 9,338.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 41.7 | 15.7 | |
| 244.5 | 15,338.5 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 66.7 | 8,171.9 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 12,295.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.5 | 5.4 | |
| 90.4 | 11,333.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 68.7 | 7,974.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26.2 | 162.6 | |
| 521.5 | 14,850.2 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.3 | |
| 107.0 | 8,256.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 339.8 | 9,569.6 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor... beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. Address: Four Tower Bridge, West Conshohocken, PA, United States, 19428 Read more
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
Headquarters
West Conshohocken, PA
Website
The share price of Madrigal Pharmaceuticals Inc (MDGL) is $530.23 (NASDAQ) as of 17-Apr-2026 13:39 EDT. Madrigal Pharmaceuticals Inc (MDGL) has given a return of 30.28% in the last 3 years.
Since, TTM earnings of Madrigal Pharmaceuticals Inc (MDGL) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-45.32
|
21.68
|
|
2024
|
-14.52
|
8.97
|
|
2023
|
-12.24
|
11.28
|
|
2022
|
-16.94
|
25.35
|
|
2021
|
-6.00
|
7.38
|
The 52-week high and low of Madrigal Pharmaceuticals Inc (MDGL) are Rs 615.00 and Rs 265.00 as of 19-Apr-2026.
Madrigal Pharmaceuticals Inc (MDGL) has a market capitalisation of $ 12,043 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Madrigal Pharmaceuticals Inc (MDGL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.